Repository logo
 
Publication

Effect of recombinant human erythropoietin in a rat model of moderate chronic renal failure – focus on inflammation, oxidative Stress and function/renoprotection

2010Journal article Open access
Simple item page
dc.contributor.authorGarrido, P.
dc.contributor.authorReis, F.
dc.contributor.authorCosta, E.
dc.contributor.authorAlmeida, A.
dc.contributor.authorParada, B.
dc.contributor.authorTeixeira-Lemos, E.
dc.contributor.authorSantos, P.
dc.contributor.authorAlves, R.
dc.contributor.authorSereno, J.
dc.contributor.authorPinto, R.
dc.contributor.authorTavares, C.A.
dc.contributor.authorFigueiredo, A.
dc.contributor.authorRocha-Pereira, P.
dc.contributor.authorBelo, L.
dc.contributor.authorSantos-Silva, A.
dc.contributor.authorTeixeira, F.
dc.date.accessioned2010-10-16T14:34:00Z
dc.date.available2010-10-16T14:34:00Z
dc.date.issued2010
dc.description.abstractBackground/Aims: Chronic renal failure (CRF) patients develop anaemia, thus promoting cardiovascular complications, which seems to be favoured by the low kidney erythropoietin (EPO) production. The renal insufficiency degree might determine the moment to start recombinant human EPO (rhEPO) therapy. It has been attributed important non-hematopoietic effects to rhEPO, which might underlie cardio and renoprotection. This work aimed to evaluate the effect of rhEPO in a rat model of moderate CRF, focusing on inflammation, oxidative stress and function/renoprotection. Methods: Four groups (n=7) of male Wistar rats were evaluated during a 15 week follow-up period: control (without treatment); rhEPO (50 IU/Kg/wk Recormon®); CRF and CRF+rhEPO. Blood samples were collected at the beginning and 3, 9 and 12 weeks after 3/4 nephrectomy, in order to evaluate: renal function, haematological parameters, iron metabolism and serum proliferative (TGF-B1), inflammatory (TNF-a, CRP, IL-2 and IL-1B) and redox status (MDA, TAS and 3-NT) markers. Kidney gene expression of Il2, Vegf, Nos2 and Nos3 were assessed by real-time PCR. Blood pressure, heart rate and tissues trophy indexes were also estimated. Results: Our data are consistent with a sustained moderate degree of CRF with development of moderate and corrected anaemia and hypertension. The remnant kidney showed a proliferative profile, with increased mass (hypertrophism), upregulated tissue Vegf gene expression, accompanied by increased levels of serum TGF-B1. Serum 3-NT was augmented, suggesting oxidative stress, which was accompanied by a trend to higher kidney Nos gene expression of both isoforms. rhEPO treatment was able to partially attenuate renal function markers, totally correct anaemia, also demonstrating a proliferative and antioxidant action, suggesting renoprotection. Conclusion: This study suggests that rhEPO therapy might be recommended in moderate CRF stages in order to efficiently correct not only the anaemia but also the underlying deleterious mechanisms, due to a proliferative and antioxidant action on the remnant kidney.por
dc.description.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.citationGARRIDO, P ...[et al.] - Effect of recombinant human erythropoietin in a rat model of moderate chronic renal failure – focus on inflammation, oxidative Stress and function/renoprotection. The Open Drug Discovery Journal. ISSN 1877-3818. Vol. 2 (2010), p. 25-32por
dc.identifier.doi10.2174/1877381801002010025
dc.identifier.eissn1877-3818
dc.identifier.urihttp://hdl.handle.net/10400.14/3018
dc.language.isoengpor
dc.publisherBentham Openpor
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectModerate chronic renal failurepor
dc.subjectErythropoietin treatmentpor
dc.subjectRenoprotectionpor
dc.subjectProliferationpor
dc.subjectInflammationpor
dc.subjectOxidative stresspor
dc.titleEffect of recombinant human erythropoietin in a rat model of moderate chronic renal failure – focus on inflammation, oxidative Stress and function/renoprotectionpor
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage32
oaire.citation.startPage25
oaire.citation.titleOpen Drug Discovery Journal
oaire.citation.volume2
person.familyNameBelo
person.givenNameLuís
person.identifier.ciencia-idC319-EED1-E15D
person.identifier.orcid0000-0002-3941-6850
person.identifier.ridK-5878-2013
person.identifier.scopus-author-id6602879850
rcaap.rightsopenAccesspor
rcaap.typearticlepor
relation.isAuthorOfPublication3654b7b5-7ad2-4f2f-9114-93dc094f8e9e
relation.isAuthorOfPublication.latestForDiscovery3654b7b5-7ad2-4f2f-9114-93dc094f8e9e

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
com-inter_2010_ICS_1630_Costa_Elisio_3.pdf
Size:
854.73 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FCSE - Contribuições em Revistas Científicas / Contribution to Journals